A cohort of convalescent Ebola hemorrhagic fever (EHF) patients and their household contacts (HHCs) were studied prospectively to determine if convalescent body fluids contain Ebola virus and if secondary transmission occurs during convalescence. Twenty-nine EHF convalescents and 152 HHCs were monitored for up to 21 months. Blood specimens were obtained and symptom information was collected from convalescents and their HHCs; other body fluid specimens were also obtained from convalescents. Arthralgias and myalgia were reported significantly more often by convalescents than HHCs. Evidence of Ebola virus was detected by reverse transcription -polymerase chain reaction in semen specimens up to 91 days after disease onset; however, these and all other non-blood body fluids tested negative by virus isolation. Among 81 initially antibody negative HHCs, none became antibody positive. Blood specimens of 5 HHCs not identified as EHF patients were initially antibody positive. No direct evidence of convalescent-to-HHC transmission of EHF was found, although the semen of convalescents may be infectious. The existence of initially antibody-positive HHCs suggests that mild cases of Ebola virus infection occurred and that the full extent of the EHF epidemic was probably underestimated.
From January to June 1995, the city of Kikwit, Democratic shown to exist in the semen of a convalescent patient for up to 83 days after disease onset and may have been the source Republic of the Congo (DRC), was the focus for an epidemic of Ebola (EBO) hemorrhagic fever (EHF) that involved an of infection to a contact [3 -5] ; and Marburg virus has also been isolated from the anterior chamber of the eye of a convalescent additional 20 villages in the Kwilu subregion. There were 315 cases, of whom 244 died [1] . Many of the survivors of the patient with uveitis 80 days after disease onset [6] . We conducted a prospective study of patients who recovered epidemic returned home to their families. Because little was known about their infectiousness, most hospitalized patients from EBO (subtype Zaire; EBO-Z) virus infection to investigate the potential for sexual and nonsexual transmission. The were held in an observation ward for 3 weeks after recovering from their acute illness before they were allowed to be disobjectives of the study were to describe the clinical course of convalescence following EHF, determine whether body fluids charged.
There is evidence that convalescent EHF patients may be of convalescent EHF patients contain EBO virus and quantify the duration of infectivity, and monitor household contacts infectious: EBO virus has been isolated from the semen of a convalescent 61 days after disease onset [2] ; Marburg virus, a (HHCs) for evidence of secondary transmission from the convalescents. filovirus that is genetically related to EBO virus, has been Follow-Up of Convalescent EHF Patients study, convalescents were defined as persons who had laboratory fluid specimens were obtained from the convalescents: urine, feces (from a rectal swab), tears, sweat, saliva, semen (ejaculate was evidence of EBO infection and had recovered from the acute phase of their illness.
collected in a latex condom), and vaginal secretions (from a vaginal swab). None of the convalescents was lactating, so no breast milk An HHC was any person who resided in the same household as or shared a cooking fire with an EHF convalescent at the time was collected. On subsequent visits during the first 6 months of follow-up, a of enrollment. HHCs were considered to have been infected with EBO-Z virus if they had an initial blood specimen that tested standardized questionnaire was administered to participants about intercurrent illnesses and contact with the convalescent. Audiometnegative for IgM and IgG antibodies and EBO antigen and a subsequent specimen that was positive for one or more of these three ric testing was also performed, and a full set of body fluid specimens was obtained from the convalescents. During the first 3 tests. HHCs were considered to have EHF disease if they met the laboratory diagnostic criteria for EBO infection and if they met months of follow-up, we attempted to obtain 3 specimens of each body fluid from the convalescents. the clinical criteria for EHF as described in the paragraph above. An HHC who met the clinical criteria for EHF but who lacked To determine whether HHCs had become EBO antibody positive, a follow-up blood specimen was collected from HHCs on the laboratory confirmation of EBO infection was classified as having symptoms ''consistent with EHF.'' last visit made during the initial 6 months of the study. However, because of a mishap that occurred either during specimen storage The study protocol was approved by the Ministry of Health of the former Zairian government, Bandundu region health authorior transport, the labels on the follow-up specimen tubes were illegible, and individual specimens could not be identified; these ties, and the Centers for Disease Control and Prevention (CDC; Atlanta) Human Subjects Review Board. Convalescents and their specimens were discarded. Therefore, one additional visit was made in April 1997, 21 months after follow-up began, to obtain sex partners in the household were counseled regarding the possibility of sexual transmission of EHF, and condoms were provided.
blood specimens again. For some HHCs, only 1 specimen was obtained, and it was obtained after exposure to the convalescent All HHCs were educated about EHF, care of the convalescent person, and avoidance of the convalescent's body fluids. Latex had begun. When such a specimen tested negative for anti-EBO IgG antibody, we assumed that the HHC had been antibody negagloves were provided in case contact with a convalescent's body fluids could not be avoided. The convalescents who participated tive since the beginning of follow-up. During the 21-month follow-up visit, in addition to the blood were given food packages at each visit as an incentive; convalescents and their families who participated in the 21-month followspecimen that was obtained from all participants, a semen specimen was obtained from all male convalescents. A standardized inup visit were also given US$100. All convalescents who could be contacted were given a 1-month supply of iron and folate suppledepth symptom questionnaire was administered to each convalescent and up to 2 household controls. We attempted to select 2 ments, regardless of whether they chose to participate.
We used a prospective cohort design, with the beginning of the controls of the same sex as and close in age to the convalescent. During the in-depth symptom interview, we first asked a series of follow-up period defined as the date of discharge of the convalescent from the EBO isolation ward of Kikwit General Hospital. For close-ended questions about symptoms that occurred in the past month; then in an open-ended format, we asked the interviewee the 2 convalescents who were never hospitalized, follow-up began on the day of symptom onset. As soon as the study protocol was to describe the major health problems that he or she had experienced in the past year. Because of the civil unrest that affected approved, we began contacting potential convalescents for enrollment. Some potential convalescents had already been discharged Bandundu region, the field work to complete the 21-month followup visits was prematurely terminated. All interviews were confrom the hospital, while others were held for observation in an open ward of the hospital. Potential convalescents who were enducted by a single team of Congolese health workers in either French or Kikongo, the native language of the participants. rolled were later dropped from the study if they lacked laboratory evidence of EBO infection.
In the course of other epidemiologic studies and serologic surveillance activities that were conducted in Kikwit during the EHF Data and specimen collection. After enrollment, participants were visited by the study team up to six times over the first 6 epidemic, a small number of additional blood specimens were obtained from convalescents and their HHCs who participated in months and once at 21 months. On the initial visit, the EHF convalescent and his or her HHCs were interviewed regarding any sympthis study. These specimens were tested by the same laboratory that analyzed the specimens collected for this study, and results toms experienced since the convalescent's release from the hospital. Convalescents were examined by a physician on the study from these additional specimens were included in this analysis.
Laboratory. All specimens were tested by the Special Pathoteam. Because of anecdotal reports of hearing loss during acute EHF, audiometric testing (model 92680; Welch Allyn, Skaneateles gens Branch, Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, CDC. Virus isolation was attempted Falls, NY) for hearing loss of four frequencies (500, 1000, 2000, and 4000 Hz) at a 25-decibel level was performed on convalescents on all body fluid specimens, and they were also tested with an ELISA to detect EBO virus protein antigens [7, 8] . Blood speciand 2 household controls closest in age to the convalescent. In addition, HHCs were asked about their exposure to the convalesmens were tested by ELISA for the presence of EBO antigen and IgM and IgG antibodies [7, 8] . Semen specimens were also tested cent, including whether they had touched, embraced, or kissed a convalescent; had slept in the same bed or had sexual intercourse for the presence of viral RNA, using reverse transcription-polymerase chain reaction (RT-PCR) [9] . with a convalescent; or had other exposures to the body fluids of a convalescent. If an HHC reported having sexual intercourse with Statistical analysis. For visits completed during the first 6 months of follow-up, we calculated the proportion of interviews a convalescent, he or she was asked whether a condom was used always, sometimes, or never. A blood specimen was obtained from in which a symptom was reported. Proportions were calculated separately for convalescents and HHCs. Odds ratios (ORs) for the all convalescents and their HHCs. The following additional body comparison of symptoms between convalescents and HHCs were were only visited once; therefore, there was no need to analyze these data with a method for correlated data. Instead, comparisons of symptom frequency were made using a logistic regression method, which added 0.5 to zero cells of stratum-specific tables During the initial 6 months of follow-up, convalescents gave without a zero marginal [11] . ORs were adjusted for sex and age a median of 5 interviews per person (range: 1 -6); the median group using age terciles. blood specimens from the 29 convalescents enrolled in the study: 353 specimens were collected during the first 6 months of follow-up and 20 specimens were collected at the 21-month Results follow-up visit. A median of 10 (range: 2 -31) specimens was obtained from each convalescent.
Enrollment, follow-up, and epidemiologic characteristics of
As required by the case definition, all convalescents had at the study population. From 20 June to 24 July 1995, we least 1 blood specimen that tested positive for antigen or IgM identified 58 patients from the epidemic surveillance database or IgG antibody. The earliest specimen that tested positive for who met the clinical criteria of the convalescent EHF case antigen was obtained 3 days after symptoms began; however definition; 49 of them lived in or near Kikwit. Of these 49 only 1 specimen was obtained earlier in a convalescent's illness potential convalescents, 32 agreed to participate, 14 refused, 2 (figure 1). All specimens obtained 3 -6 days after symptoms could not be located, and 1 was found to be antibody negative began tested positive for antigen, and antigen positivity disapduring the enrollment period and was dropped from the study. peared 7 -16 days after symptoms began. All convalescents Of the 32 potential convalescents who agreed to participate, tested were antigen negative after 16 days. Results from tests 29 were included in the study because they were antibody for IgM antibody showed that IgM appears between 2 and 9 positive and therefore met the complete case definition for an days after symptom onset, and disappears between 30 and 168 EHF convalescent. These 29 convalescents lived in 27 housedays after onset. Since the convalescent who tested positive holds: 25 households each contained 1 convalescent, and 2
for IgM 168 days after symptom onset had no subsequent households each contained 2 convalescents. Table 1 shows specimens tested for IgM, we were unable to determine whether the epidemiologic characteristics of the serologically confirmed antibody persists ú168 days. IgG antibody appears between EHF convalescents who were included in the study. days 6 and 18 after symptom onset and persists. All 20 of the All 152 HHCs of the 29 participating convalescents were specimens drawn at the 21-month follow-up visit (661 -749 enrolled. The median age of the HHCs was 15 years (range: 3 months to 58 years), and 74 (48.7%) were female. days after symptom onset) were IgG positive. Eleven specimens were negative for all tests (7 were tested quently than did HHCs (table 3) . The odds of a convalescent reporting fever, headache, diarrhea, dysphagia, hiccups, or for antigen and IgM and IgG antibody, and 4 were tested for only IgM and IgG). Of the latter group, 2 of the 4 specimens signs of hemorrhage (conjunctival or gingival bleeding, petechiae, melena, and hematemesis) were not significantly differwere obtained in the first week after symptoms began and thus may have been antigen positive. If these 2 early specimens were ignored, then 9 (2.4%) of 371 specimens tested negative for antigen, IgM, and IgG. However, all patients with a negative obtained 701 days after the onset of illness [9] .
RT-PCR 0
Clinical symptoms of convalescents. During the first 6 months of follow-up, convalescents reported arthralgias, myal- ent from those of HHCs. Arthralgias and myalgia were the were red or swollen. Almost all joint involvement was symmetric, and 3 -5 pairs of joints were typically involved. From most most commonly reported symptoms among convalescents: The proportions of convalescents reporting these symptoms at least to least commonly affected, the joints reportedly involved were the knees, back, hips, fingers, wrists, neck, shoulders, ankles, once during the first 6 months of follow-up were 23 (79.3%) and 16 (55.2%), respectively. Physical examinations of inand elbows. Serial audiometric testing was performed on 28 of the 29 volved joints did not reveal redness, swelling, or reduced range of motion with passive movement.
convalescents during follow-up visits (median of 3 tests per convalescent; range: 1 -4). Among these 28 convalescents, 11 Fifteen months later, at the 21-month follow-up visit, convalescents reported both general and specific health problems.
(39.3%) could not hear at least one of four frequencies at some point during the first 6 months of follow-up. Among 8 Compared with their health before the EBO epidemic, convalescents reported more often than controls that their general convalescents who had follow-up at 21 months and who had denied having hearing problems before their EBO infections, health was a little or much worse (70.0% vs. 17.9%; OR: 8.1; 95% CI: 1.7 -37.7) and that their capacity to work was worse 7 still could not hear at least one frequency; however, only 4 had self-reported hearing loss. After adjusting for age and sex, (70.0% vs. 7.1%; OR: 13.6; 95% CI: 2.7 -69.1). Regarding specific symptoms, only arthralgias and myalgia were reported we failed to show a significant association between being a convalescent and hearing loss, defined either audiometrically significantly more often by convalescents than controls. Excluding those who had myalgia before the EBO epidemic, 9
(OR: 1.4; 95% CI: 0.4 -5.0) or subjectively (OR: 3.5; 95% CI: 0.3 -39.6). (47.4%) of 19 convalescents and 1 (3.7%) of 27 controls reported having myalgia at least once a week during the month Serologic results and symptoms of HHCs of convalescents. We tested 160 blood specimens from HHCs enrolled in the preceding the interview (OR: 8.8; 95% CI: 1.9 -42.0); and 5 (26.3%) of 19 convalescents and none of 27 controls described study. A median of 1 specimen was collected (range: 1 -6) and §2 blood specimens were obtained from 49 HHCs (32.2%). myalgia as a major health problem affecting them in the past year (OR: 5.3; 95% CI: 0.9 -31.2).
Of 152 HHCs, 5 had serologic evidence of EBO virus infection on their initial specimen, 81 were antibody negative on their Excluding those who had arthralgias before the EBO epidemic, 8 (61.5%) of 13 convalescents and 1 (3.8%) of 26 initial specimen and were serologically monitored prospectively, 16 had an antibody-negative specimen obtained through controls reported having arthralgias at least once a week during the month preceding the interview (OR: 16.6; 95% CI: 2.5 -surveillance efforts before enrollment began but had no subsequent specimens and thus had no serologic follow-up; no blood 107.6), and 9 (64.3%) of 14 convalescents and none of 26 controls described arthralgias as a major health problem affectspecimens were obtained from 50 HHCs. Five HHCs (HHCs A-E) had serologic evidence of EBO virus ing them in the past year (OR: 18.0; 95% CI: 2.5 -128.7). The median summed optical density (SOD) of the ELISA test for infection on their initial specimen. HHC A had a single IgGpositive specimen obtained 6 days before she had exposure to a IgG antibody was significantly greater for convalescents with arthralgias (median SOD Å 3.90) than for convalescents withconvalescent. The timing of her serologic results excluded the convalescent as the source of the infection. She had a spontaneous out arthralgias (median SOD Å 2.13; P Å .045).
Most convalescents who reported arthralgias at 21 months abortion 3 days before her specimen was obtained, but otherwise she had no symptoms of EHF during the study period. also reported muscle or joint pain during the acute phase of EHF. Arthralgias usually were worse in the morning and after HHCs B and C each had a single IgG-positive specimen (antigen-and IgM-negative) and no symptoms consistent with working, and convalescents rarely reported that painful joints S33 JID 1999;179 (Suppl 1) Follow-Up of Convalescent EHF Patients EHF during the study period. Assuming a minimum incubation antibody-negative result and 50 from whom no blood specimens were obtained), 3 experienced 3 episodes of symptoms period of 2 days for EHF [12] and a minimum of 30 days between symptom onset and IgG-positivity (figure 1), we esticonsistent with EHF. We identified 2 episodes during the first 4 months of follow-up and 1 at the 21-month follow-up visit. mated that these HHCs were infected at least 32 days before the blood specimen was obtained. Assuming the reported conDuring the follow-up period, we identified 2 deaths among HHCs. The first was a 9-year-old boy whose cause of death tact dates are accurate, since the exposure of HHCs B and C to convalescents began 18 and 19 days, respectively, before was reported as poisoning, and no symptoms were reported. A second death occurred in a 2-week-old infant; the child was the blood specimens were obtained, it seems unlikely that the source of EBO virus for these HHCs was the convalescent.
born prematurely, and because he only lived 2 weeks, he was never enrolled in the study. One specimen was obtained from HHC D 3 days after her exposure to the convalescent: The specimen was positive for
Other serologic results. Among 22 household members of 3 suspected EHF cases who ultimately were found to be antiboth IgM and IgG antibodies. During the following 3 months, 3 more specimens were obtained from HHC D, and they were body negative, 2 had laboratory evidence of EBO virus infection (HHCs F and G). HHC F had no reported symptoms and positive for IgG only. A fifth specimen obtained 20 months after her exposure was negative for IgG. She had no symptoms a single blood specimen. The specimen was divided into two portions: One portion was weakly EBO IgM positive, while consistent with EHF during the study period. Using the same argument as above and making the additional assumption that the other was IgM negative. Neither portion was positive for antigen or IgG. HHC G was asymptomatic until the 21-month a minimum of 6 days elapses between symptom onset and combined IgM and IgG positivity (figure 1), we estimated that follow-up visit, at which time she reported fever, headache, abdominal pain, and back pain during the 15 months since the the EBO virus infection of HHC D occurred at least 8 days before the blood specimen was obtained (i.e., 5 days before previous study visit. Her only specimen, which was obtained at the 21-month follow-up visit, was positive for EBO IgG. she was exposed to the convalescent in her household). If the reported contact dates are accurate, it would seem unlikely that the source of the EBO virus was the convalescent.
Discussion HHC E was a 20-year-old woman who had no symptoms consistent with EHF during the study period. Her initial speci-
The primary public health issue addressed by this study was to assess whether convalescent EHF patients who had returned men was weakly positive for IgM, and a follow-up specimen 21 months later was IgG negative. Since the IgM result from home posed any danger of transmitting EBO virus to their HHCs. On the basis of clinical and serologic criteria of a cohort the first specimen could have been a false-positive or the IgG from the second specimen could have been a false-negative, it followed for up to 21 months, we found no direct evidence of convalescent-to-HHC transmission of EBO-Z virus. However, is difficult to determine whether this HHC was infected with the EBO virus. If she had been infected with EBO, it is possible for 4 of the 5 male convalescents from whom semen specimens were obtained, we demonstrated the presence of EBO virus that her infection was sexually transmitted. The IgM-positive specimen was obtained 52 days after her exposure to the conva-RNA in the semen up to 91 days after illness onset. Furthermore, we have indirect evidence that 1 HHC may have been lescent had begun. The semen of the convalescent, with whom HHC E reported having sexual intercourse, was positive for infected by exposure to semen. These findings are consistent with those in previous reports of EBO virus and Marburg virus EBO virus RNA as determined by RT-PCR, and condoms were not always used.
being isolated from the semen of convalescents [2 -4] and Marburg virus being implicated in a potentially sexually transIn summary, of the 5 initially antibody-positive HHCs, there is indirect evidence that 1 may have been infected by a convamitted case [5] . In the 6 months following their recovery from the acute lescent and that the infection may have been sexually transmitted via semen. Of the remaining 4 HHCs, only 1 reported a phase of EHF, convalescents experienced arthralgias, myalgia, abdominal pain, extreme fatigue, and anorexia; however, many symptom consistent with EHF, and all had histories of exposure to convalescents that began after the time we estimated they of these symptoms seemed to resolve by the 21-month followup visit. A striking finding was that almost two-thirds of the were infected with the EBO virus.
Among the 81 HHCs who were antibody negative on their survivors continued to suffer from arthralgias or myalgia 21 months after their acute illness, and many described their sympinitial specimen and were serologically monitored, none seroconverted. However, during serologic follow-up, 15 of these toms as major health problems. Symmetric polyarthropathies have been associated with other virus infections, such as hepati-81 HHCs experienced 18 episodes of symptoms that were consistent with EHF. After serologic follow-up ended, prospective tis B, rubella, and parvovirus [13] . These arthropathies result from either viral replication or the deposition of immune commonitoring of symptoms continued, and 7 additional episodes of symptoms consistent with EHF were identified among 6 plexes in joint tissue. In this study, antibody levels were greater among convalescents with arthralgias, suggesting a role of perHHCs. Five episodes occurred during the first 4 months of follow-up and two at the 21-month follow-up visit. was the potential for misclassification of serologic results (false-positives and false-negatives). This problem became eviThroughout the study, we discovered HHCs had episodes of symptoms that were consistent with the outbreak definition of dent when a few specimens that were retested several times yielded conflicting results. Fourth, there was the potential for EHF (fever and three accompanying symptoms or unexplained bleeding). All the episodes that occurred among HHCs for misclassification of symptoms. The clinical criteria of the outbreak definition of EHF are nonspecific, and as already menwhom we had a blood specimen were demonstrated not to be EHF because the HHCs were antibody negative. In central tioned, have numerous other causes. While serologic results were usually sufficient to rule out EHF, in instances where no Africa, there are many possible causes for fevers (e.g., malaria, yellow fever, dysentery, and hepatitis), constitutional sympresults were available, we found it difficult to interpret the symptoms that were reported. This problem underscores the toms, and bleeding episodes. That antibody negative HHCs frequently met the clinical criteria for EHF underscores the importance of serologic confirmation. Finally, responses to the in-depth questionnaire that we used to characterize the longpoint that the outbreak case definition should not be used for endemic disease detection, and it points to the necessity of term clinical sequelae of EHF were subject to recall error, and comparisons were subject to recall bias, particularly with regard etiologic diagnosis.
This study provides evidence for asymptomatic or mild cases to the timing of symptoms that may have occurred months or years in the past. of EBO virus infection. We identified at least 4 HHCs who had laboratory evidence of IgG antibodies without symptoms when they were initially interviewed, suggesting disease conConclusions current or prior to that of the family member first enrolled as a convalescent in the study. One of these asymptomatic On the basis of the results of this study, we make the followindividuals was among the contacts of a suspected EHF case ing recommendations. First, since we found no direct evidence who was subsequently excluded from our study because she of convalescent-to-HHC transmission of EBO-Z virus and we did not have laboratory evidence of disease. In addition, 3 were unable to detect virus by culture from any of our study children of an EHF patient who was reported to the epidemic participants, EHF convalescents should be allowed to return surveillance system but not enrolled in this study because of home after resolution of their acute illness. However, since death, were IgM-positive for EBO virus infection, suggesting EBO virus RNA was detected by RT-PCR in samples collected infection but asymptomatic disease (data not shown). Thereup to 91 days after illness onset, further study is warranted. fore, it is valid to test for asymptomatic infection among con-EHF convalescents and their contacts should be followed in a tacts of convalescents. These findings also suggest that the full research setting that includes screening of body fluids, espeextent of the Kikwit epidemic was underestimated. cially semen; educating contacts to avoid body fluids, espeOne antibody-positive HHC, who we suspected may have cially semen; and providing latex gloves when contact with been infected through contact with a convalescent, had IgM body fluids is unavoidable. Furthermore, condoms should be antibodies on her initial specimen but no IgG. She reported no provided for 3 months to prevent potential sexual transmission symptoms and did not develop IgG antibodies by day 687. A of EBO. A key question to be addressed by such a study is second HHC had IgM initially and IgG antibodies through day whether semen is infectious, and if so, for how long. Second, 97, but she had no IgG on day 629. These findings suggest we recommend that in a future EHF outbreak, surveys should that IgG may not develop or may be transient in mild cases.
be conducted to characterize the full spectrum of the illness Alternatively, misclassification error could explain these anomand to prevent transmission that might otherwise have occurred alous findings.
unnoticed from mild cases. Surveys should not be delayed, There are several important limitations to this study. First, since people with mild or asymptomatic infections may have there was considerable loss to follow-up. Although we will a transient antibody response. Third, convalescents should be never know the serologic status of almost half of the HHCs screened for arthralgias and myalgia and treated appropriately. enrolled after having exposure to convalescents, at least we Finally, work should continue to improve rapid diagnostic can say that during the first 6 months of follow-up, there were assays because in nonepidemic situations, the clinical case no cases of serious, unexplained illness or death that appeared definition is too nonspecific to be useful. to be due to EHF. This suggests that the consequences most feared by the HHC of EHF convalescents were not occurring.
